Skip to main content
Fig. 1 | Advances in Rheumatology

Fig. 1

From: Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort

Fig. 1

Disease activity scores and treatment responses in patients with AS or PsA during therapy with secukinumab. a) Mean values (± standard deviation) of ASDAS-CRP and DAS28-CRP at baseline and at 8, 24 and 52 weeks of treatment in patients with AS and PsA, respectively. *P < 0.05, ****P < 0.0001 (compared to week 0); ##P < 0.01, ####P < 0.0001 (week 24 vs. 8); ++P < 0.01, +++P < 0.001 (week 52 vs. 24). b) Numbers and percentages of AS or PsA patients with different disease activity states according to ASDAS and DAS28 cut-offs. VHDA, very high disease activity (ASDAS > 3.5); HDA, high disease activity (2.1 ≤ ASDAS < 3.5 or DAS28 > 5.1); MDA, moderate disease activity (3.2 < DAS28 ≤ 5.1); LDA, low disease activity (ASDAS < 2.1 or DAS28 ≤ 3.2); inactive disease or remission (ASDAS < 1.3 or DAS28 < 2.6). *P < 0.05 (LDA at week 8 in AS vs. PsA). c) Median changes of ASDAS-CRP and DAS28-CRP at the various time points in patients with AS and PsA, respectively. ΔASDAS ≥ 1.1, clinically important improvement; ΔASDAS ≥ 2, major improvement; ΔDAS28 > 1.2, moderate response with current DAS28 > 3.2 or good response with current DAS28 ≤ 3.2. **P < 0.01, ****P < 0.0001 (compared to week 0); ##P < 0.01, ####P < 0.0001 (week 24 vs. 8); +P < 0.05 (week 52 vs. 24). d) Numbers and percentages of AS or PsA patients with different treatment responses according to ASAS and EULAR criteria (see above cut-offs). *P < 0.05 (significant responses at week 8 in PsA vs. AS).

Back to article page